ZÜRICH, July 3 /PRNewswire/ -- Solianis recently signed an investment agreement with a Swiss foundation
which invests its assets in Swiss companies. According to the agreement, this
foundation will put CHF 5 million, while the previous investors in Solianis
are investing another CHF 3 million.
"The CHF 8 million invested will enable us to increase our efforts to
complete the prototype of our non-invasive glucose monitoring device and to
prepare the clinical trials required for CE certification. The realisation of
our innovative product concept is now assured", says Mario Stark, managing
director at Solianis.
Dr. Andreas Bänziger, member of Solianis' Board of Directors, confirms
that "Solianis convinced the foundation with its technology, successful tests
and expert team. Together with former and new investors we will implement our
project and are able to take the steps necessary to be ready for market
introduction".
Solianis Monitoring AG is a medical devices company developing
a non-invasive Continuous Glucose Monitor (CGM) for self-monitoring patients
with diabetes. Its technology is based on a unique and proprietary
multisensor technology for monitoring physiological parameters. Solianis'
non-invasive device delivers comparable results to the minimally invasive
devices currently approved by the FDA.
Solianis was incorporated in May 2005, and is funded by
private investors and the Pioneer Fund of the Cantonal Bank of Zürich. The
company plans to introduce its first-generation device for insulin-dependent
patients with diabetes by 2010 in Europe, after CE approval. Later product
generations will target all patients with diabetes and impaired glucose
tolerance.
Contact: Solianis Monitoring AG
Mario Stark
Tel: +41-44-306-80-40
Mob: +41-79-542-88-74
mario.stark@solianis.com
http://www.solianis.com
SOURCE: Solianis Monitoring AG
